Ad is loading...
MENU

KNSA Stock Kiniksa Pharmaceuticals International (KNSA, $23.27) Moving Average Convergence Divergence (MACD) Histogram turned negative on October 29, 2024

A.I.dvisor
at Tickeron.com
Loading...
KNSA - Kiniksa Pharmaceuticals International plc
MACD signal
Bearish Trend
Odds of DOWN Trend
Tickeron
MACD signal
Price: $23.27
Daily change: -$4.33 (-15.68%)
Daily volume: 973.7K
Industry: Biotechnology
This is a Bearish indicator signaling KNSA's price could decline from here. Traders may explore shorting the stock or put options. A.I. dvisor identified 52 similar cases where KNSA's MACD histogram became negative, and of them led to successful outcomes. Odds of Success:

Momentum Indicator for KNSA turns negative, indicating new downward trend

KNSA saw its Momentum Indicator move below the 0 level on October 29, 2024. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 91 similar instances where the indicator turned negative. In of the 91 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for KNSA turned negative on October 29, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at .

KNSA moved below its 50-day moving average on October 29, 2024 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for KNSA crossed bearishly below the 50-day moving average on November 01, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where KNSA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for KNSA's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 67 cases where KNSA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where KNSA advanced for three days, in of 304 cases, the price rose further within the following month. The odds of a continued upward trend are .

KNSA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. KNSA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.517) is normal, around the industry mean (14.849). P/E Ratio (164.538) is within average values for comparable stocks, (95.928). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.788). KNSA has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (4.036) is also within normal values, averaging (211.128).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

View a ticker or compare two or three
KNSA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of pharmaceutical products

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
2 Church Street
Phone
+44 8081896257
Employees
297
Web
https://www.kiniksa.com